当前位置:
X-MOL 学术
›
Oncoimmunology
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results
OncoImmunology ( IF 6.5 ) Pub Date : 2019-10-21 , DOI: 10.1080/2162402x.2019.1677139 Thilo Gambichler 1 , Maria Chatzipantazi 1 , Ulrike Schröter 1 , E. Stockfleth 1 , Cansu Gedik 1
OncoImmunology ( IF 6.5 ) Pub Date : 2019-10-21 , DOI: 10.1080/2162402x.2019.1677139 Thilo Gambichler 1 , Maria Chatzipantazi 1 , Ulrike Schröter 1 , E. Stockfleth 1 , Cansu Gedik 1
Affiliation
Background: Melanoma of unknown primary (MUP) is an uncommon clinical subtype of melanoma of known primary (MKP).
中文翻译:
原发性未知的黑色素瘤患者在免疫检查点抑制剂治疗下比原发性已知的患者表现出更好的结果:初步结果
背景:未知原发性黑色素瘤(MUP)是已知原发性黑色素瘤(MKP)的罕见临床亚型。
更新日期:2019-10-25
中文翻译:
原发性未知的黑色素瘤患者在免疫检查点抑制剂治疗下比原发性已知的患者表现出更好的结果:初步结果
背景:未知原发性黑色素瘤(MUP)是已知原发性黑色素瘤(MKP)的罕见临床亚型。